BioCentury | Nov 2, 2015
Company News

BioTime, Heraeus Medical deal

...BioTime’s OrthoCyte Corp. subsidiary and Heraeus granted each other rights to their respective technologies to develop...
...cell technology, and either BioTime’s HyStem scaffold technology or Heraeus’ scaffold technology. BioTime’s license to Heraeus...
...the cell therapy product for all osteoskelton diseases and injuries, except oral maxilla-facial, using HyStem. Heraeus’...
BioCentury | Jun 29, 2015
Financial News

Ankasa completes venture financing

...Gene/Cell therapy, Musculoskeletal Date completed: 2015-06-23 Type: Venture financing Raised: $8.5 million Investors: Avalon Ventures; Heraeus...
BioCentury | Jun 24, 2015
Financial News

Ankasa raises $8.5M in series A tranche

...a planned $17 million series A round led by new investor Avalon Ventures. New investors Heraeus...
BioCentury | Jan 26, 2015
Company News

Locate, Heraeus Medical deal

...Heraeus an exclusive license to IP covering Locate’s TAOS thermo-responsive polymer technology for orthopedic applications. Heraeus...
...Locate said terms of the deal are not disclosed. Locate Therapeutics Ltd. , Nottingham, U.K. Heraeus...
BioCentury | May 19, 2014
Company News

Curetis, Heraeus Medical sales and marketing update

...provides reagents to complete the analysis. The system and cartridge each have CE Mark approval. Heraeus...
...2012 to develop the cartridge (see BioCentury, Oct. 1, 2012). Curetis AG , Holzgerlingen, Germany Heraeus...
BioCentury | Oct 1, 2012
Company News

Curetis, Heraeus Medical deal

...Curetis and Heraeus partnered to jointly develop a Unyvero cartridge to detect pathogens and antibiotic resistances...
...and the cartridge and application will be sold by Curetis as an in vitro diagnostic. Heraeus'...
...to the product, while Curetis will pay a sales commission for any customer referrals by Heraeus...
BioCentury | Jun 6, 2005
Company News

Antisoma, Heraeus Group deal

...agent (TTA) for cancer in the first half of 2006. Antisoma plc (LSE:ASM), London, U.K. Heraeus...
BioCentury | Jul 16, 2001
Finance

Ebb & Flow

...had fallen to 75.5p the week prior, when the company entered an agreement with W.C. Heraeus...
BioCentury | Jul 16, 2001
Company News

Antisoma, W.C. Heraeus GmbH & Co. KG deal

...ASM expects to start Thioplatin trials in 2002. Antisoma plc (LSE:ASM; EASD:ASOM), London, U.K. W.C. Heraeus...
BioCentury | Jul 11, 2001
Company News

Antisoma, Heraeus in manufacturing deal

...Antisoma (LSE:ASM; EASD:ASOM) entered a cooperation and supply agreement for Thioplatin with W.C. Heraeus (Hanau, Germany...
Items per page:
1 - 10 of 10
BioCentury | Nov 2, 2015
Company News

BioTime, Heraeus Medical deal

...BioTime’s OrthoCyte Corp. subsidiary and Heraeus granted each other rights to their respective technologies to develop...
...cell technology, and either BioTime’s HyStem scaffold technology or Heraeus’ scaffold technology. BioTime’s license to Heraeus...
...the cell therapy product for all osteoskelton diseases and injuries, except oral maxilla-facial, using HyStem. Heraeus’...
BioCentury | Jun 29, 2015
Financial News

Ankasa completes venture financing

...Gene/Cell therapy, Musculoskeletal Date completed: 2015-06-23 Type: Venture financing Raised: $8.5 million Investors: Avalon Ventures; Heraeus...
BioCentury | Jun 24, 2015
Financial News

Ankasa raises $8.5M in series A tranche

...a planned $17 million series A round led by new investor Avalon Ventures. New investors Heraeus...
BioCentury | Jan 26, 2015
Company News

Locate, Heraeus Medical deal

...Heraeus an exclusive license to IP covering Locate’s TAOS thermo-responsive polymer technology for orthopedic applications. Heraeus...
...Locate said terms of the deal are not disclosed. Locate Therapeutics Ltd. , Nottingham, U.K. Heraeus...
BioCentury | May 19, 2014
Company News

Curetis, Heraeus Medical sales and marketing update

...provides reagents to complete the analysis. The system and cartridge each have CE Mark approval. Heraeus...
...2012 to develop the cartridge (see BioCentury, Oct. 1, 2012). Curetis AG , Holzgerlingen, Germany Heraeus...
BioCentury | Oct 1, 2012
Company News

Curetis, Heraeus Medical deal

...Curetis and Heraeus partnered to jointly develop a Unyvero cartridge to detect pathogens and antibiotic resistances...
...and the cartridge and application will be sold by Curetis as an in vitro diagnostic. Heraeus'...
...to the product, while Curetis will pay a sales commission for any customer referrals by Heraeus...
BioCentury | Jun 6, 2005
Company News

Antisoma, Heraeus Group deal

...agent (TTA) for cancer in the first half of 2006. Antisoma plc (LSE:ASM), London, U.K. Heraeus...
BioCentury | Jul 16, 2001
Finance

Ebb & Flow

...had fallen to 75.5p the week prior, when the company entered an agreement with W.C. Heraeus...
BioCentury | Jul 16, 2001
Company News

Antisoma, W.C. Heraeus GmbH & Co. KG deal

...ASM expects to start Thioplatin trials in 2002. Antisoma plc (LSE:ASM; EASD:ASOM), London, U.K. W.C. Heraeus...
BioCentury | Jul 11, 2001
Company News

Antisoma, Heraeus in manufacturing deal

...Antisoma (LSE:ASM; EASD:ASOM) entered a cooperation and supply agreement for Thioplatin with W.C. Heraeus (Hanau, Germany...
Items per page:
1 - 10 of 10